company background image
A226950 logo

OliX Pharmaceuticals KOSDAQ:A226950 Stock Report

Last Price

₩13.43k

Market Cap

₩222.8b

7D

-8.9%

1Y

-26.6%

Updated

14 Jun, 2024

Data

Company Financials

OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩222.8b

A226950 Stock Overview

Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.

A226950 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OliX Pharmaceuticals, Inc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OliX Pharmaceuticals
Historical stock prices
Current Share Price₩13,430.00
52 Week High₩25,950.00
52 Week Low₩12,900.00
Beta0.78
1 Month Change-11.64%
3 Month Change-18.26%
1 Year Change-26.61%
3 Year Change-67.16%
5 Year Change-47.33%
Change since IPO-59.05%

Recent News & Updates

Recent updates

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13
OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17
Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Shareholder Returns

A226950KR BiotechsKR Market
7D-8.9%-3.1%1.1%
1Y-26.6%12.6%3.7%

Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 13.8% over the past year.

Return vs Market: A226950 underperformed the KR Market which returned 4.4% over the past year.

Price Volatility

Is A226950's price volatile compared to industry and market?
A226950 volatility
A226950 Average Weekly Movement6.2%
Biotechs Industry Average Movement7.6%
Market Average Movement5.0%
10% most volatile stocks in KR Market11.2%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A226950's share price has been volatile over the past 3 months.

Volatility Over Time: A226950's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201073Dong-Ki Leewww.olixpharma.com

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.

OliX Pharmaceuticals, Inc Fundamentals Summary

How do OliX Pharmaceuticals's earnings and revenue compare to its market cap?
A226950 fundamental statistics
Market cap₩222.84b
Earnings (TTM)-₩19.00b
Revenue (TTM)₩15.58b

14.3x

P/S Ratio

-11.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A226950 income statement (TTM)
Revenue₩15.58b
Cost of Revenue₩179.23m
Gross Profit₩15.40b
Other Expenses₩34.40b
Earnings-₩19.00b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.15k
Gross Margin98.85%
Net Profit Margin-122.00%
Debt/Equity Ratio116.1%

How did A226950 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.